Search

Displaying results 3141 - 3150 of 10000 in total
  1. Drug

    Asparagine

    go.drugbank.com/drugs/DB00174
    ApprovedNutraceuticalWithdrawn

    A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase.

  2. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia

  3. Drug

    Tranylcypromine

    go.drugbank.com/drugs/DB00752
    ApprovedInvestigational

    It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). … This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression.

  4. Drug

    Pyruvic acid

    go.drugbank.com/drugs/DB00119
    ApprovedInvestigationalNutraceutical

    An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures.

  5. Drug

    Levobunolol

    go.drugbank.com/drugs/DB01210
    Approved

    A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.

  6. Drug

    Neratinib

    go.drugbank.com/drugs/DB11828
    ApprovedInvestigational

    Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. … Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.

  7. Drug

    Lifileucel

    go.drugbank.com/drugs/DB17107
    ApprovedInvestigational

    Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341 … ] Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.

  8. Drug

    Amlexanox

    go.drugbank.com/drugs/DB01025
    ApprovedWithdrawn

    Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population. … Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis.

  9. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … [L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed

  10. Drug

    Tiludronic acid

    go.drugbank.com/drugs/DB01133
    ApprovedVet approvedWithdrawn

    [A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763] … Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid].